4.8 Review

Safety of Proton Pump Inhibitor Exposure

Journal

GASTROENTEROLOGY
Volume 139, Issue 4, Pages 1115-1127

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2010.08.023

Keywords

Drug Safety; Side Effects; Acid Suppressive Therapy

Funding

  1. AstraZeneca
  2. Takeda
  3. Novartis Consumer
  4. Xenoport

Ask authors/readers for more resources

Proton pump (H+/K+- adenosine triphosphatase) inhibitors (PPIs) are widely used to treat patients with acid-related disorders because they are generally perceived to be safe and effective. However, as with any pharmacologic agent, they have the potential for side effects. Many studies have examined the side effects of long-term or short-term PPI exposure. We review the mechanism of action of PPIs, focusing on recently released products that might have greater risks of adverse effects than older products because of increased potency and/or duration of action. We summarize the data available on the putative adverse effects of PPI therapy and propose guidelines for clinicians who prescribe these agents to limit the potential for adverse outcomes in users of these effective therapeutic agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available